Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes

doi:10.1186/s42238-020-0016-7

Paper

Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes

Published Jan 31, 2020 · A. Abioye, O. Ayodele, A. Marinkovic

Journal of Cannabis Research

Q1 SJR score

38

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Δ9-Tetrahydrocannabivarin (THCV) is a cannabis-derived compound with unique properties that set it apart from the more common cannabinoids, such as Δ9-tetrahydrocannabinol (THC). The main advantage of THCV over THC is the lack of psychoactive effects. In rodent studies, THCV decreases appetite, increases satiety, and up-regulates energy metabolism, making it a clinically useful remedy for weight loss and management of obesity and type 2 diabetic patients. The distinctions between THCV and THC in terms of glycemic control, glucose metabolism, and energy regulation have been demonstrated in previous studies. Also, the effect of THCV on dyslipidemia and glycemic control in type 2 diabetics showed reduced fasting plasma glucose concentration when compared to a placebo group. In contrast, THC is indicated in individuals with cachexia. However, the uniquely diverse properties of THCV provide neuroprotection, appetite suppression, glycemic control, and reduced side effects, etc.; therefore, making it a potential priority candidate for the development of clinically useful therapies in the future. Hopefully, THCV could provide an optional platform for the treatment of life-threatening diseases.

Study Snapshot

THCV shows potential in weight loss and management of obesity and type 2 diabetes due to its unique properties, including neuroprotection, appetite suppression, glycemic control, and reduced side effects.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes

Sign up to use Study Snapshot

References

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study

THCV shows potential as a new therapeutic agent for glycemic control in type 2 diabetes patients, with CBD also demonstrating some benefits.

The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial

THCV may inhibit some effects of THC while potentiating others, but further research is needed due to small sample size and limited THC-induced effects.

Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol

Chronic THC treatment reduces energy intake and prevents high fat diet-induced increases in body weight and adiposity in mice, potentially due to changes in gut microbiota.

Endocannabinoid Signaling in Autism

Endocannabinoid signaling may play a key role in autism spectrum disorder, offering potential targets for innovative therapeutics.

Nicotine Administration Attenuates Methamphetamine-Induced Novel Object Recognition Deficits

Chronic nicotine intake in rats reduces novel object recognition deficits caused by methamphetamine, potentially through increased 42 nicotinic acetylcholine receptors in the hippocampus and perirhinal cortex.

Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.

Medical marijuana is effective for treating chronic pain, neuropathic pain, and spasticity due to multiple sclerosis, with evidence supporting its use for these indications.

Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

CBD and THCV are not rimonabant-like in their action and are unlikely to produce unwanted CNS effects, with distinct pharmacological profiles at CB1 receptors.

Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers

The CB1 neutral antagonist tetrahydrocannabivarin increases neural responses to rewarding and aversive stimuli, suggesting potential therapeutic activity in obesity with a lower risk of depressive side effects.

The endocannabinoid system and appetite: relevance for food reward

The endocannabinoid system plays a central role in modulating appetite and food intake, potentially offering new opportunities to optimize energy and nutrient intake for various target groups.

Citations

The relationship between cannabis and cardiovascular disease: clearing the haze.

Cannabis use may increase the risk of cardiovascular events, such as myocardial infarction, cerebrovascular accidents, arrhythmia, and heart failure, potentially mitigating its therapeutic potential.

Structural basis of THC analog activity at the Cannabinoid 1 receptor

The cryo-EM structure of HU210 reveals the differential spatiotemporal interactions between THC analogs and the Cannabinoid 1 receptor, potentially aiding in designing better medicines.

Pharmacokinetics of Oral Cannabinoid Δ8-Tetrahydrocannabivarin and Its Main Metabolites in Healthy Participants

Oral 8-THCV shows dose linearity and its main metabolite, 8-THCV-COOH, shows dose-dependent effects in healthy participants.

Exploring the therapeutic potential of cannabinoids in cancer by modulating signaling pathways and addressing clinical challenges

Cannabinoids show promising potential as anticancer agents through various mechanisms, but further large-scale randomized controlled trials are needed to validate these findings and establish standardized therapeutic protocols.

The Effect of Phytocannabinoids and Endocannabinoids on Nrf2 Activity in the Central Nervous System and Periphery

Phytocannabinoids and endocannabinoids interact with Nrf2 in the central nervous system, potentially playing a protective role against damage to neurons and glia by enhancing homeostatic processes.

Tetrahydrocannabivarin is Not Tetrahydrocannabinol.

THCV, often mistaken for THC, has distinct pharmacological activity and physiological effects, and further research is needed to determine its potential health, wellness, and therapeutic applications.

Cannabinoids: Potential for Modulation and Enhancement When Combined with Vitamin B12 in Case of Neurodegenerative Disorders

Cannabinoids, particularly CBD, show potential in modulating protein aggregation and mitochondrial dysfunction in neurodegenerative diseases, offering multifaceted neuroprotection when combined with vitamin B12.